Newsroom
Top Results
Sight Sciences Appoints Ali Bauerlein as Chief Financial Officer
PDF Version Ali Bauerlein Ali Bauerlein has been appointed Sight Sciences’ Chief Financial Officer and Treasurer, effective April 3, 2023 MENLO PARK, Calif., April 03, 2023 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ […]
Sight Sciences Reports Fourth Quarter and Full Year 2022 Financial Results
PDF Version MENLO PARK, Calif., March 13, 2023 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today reported financial results for the fourth quarter and year ended December 31, 2022 and issued financial […]
Sight Sciences Reports Third Quarter 2022 Financial Results
PDF Version MENLO PARK, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today reported financial results for the third quarter ended September 30, 2022. Recent Business Highlights Generated total revenue of $18.7 million in […]
Sight Sciences Announces Publication of Clinical Data Demonstrating Standalone Effectiveness of the OMNI® Surgical System in Pseudophakic Glaucoma Patients with Uncontrolled Pressure Following a Previous Combination Cataract Stent Procedure
Multicenter Clinical Data from Five US sites Published in International Ophthalmology Worldwide, more than one million trabecular microbypass stents have been implanted in combination with cataract surgery. Despite glaucoma medications and prior microbypass stenting, target IOP may no longer be achieved over time. During 3 to 42 months follow-up, the majority of these standalone study patients treated with OMNI regained IOP control and avoided traditional surgery.
Sight Sciences to Report Third Quarter 2022 Financial Results on November 10, 2022
PDF Version MENLO PARK, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced it will report financial results for the third quarter ended September 30, 2022, after the market close on Thursday, November […]
Sight Sciences OMNI® Surgical System to Be Featured in Multiple Presentations at the 2022 European Society of Cataract and Refractive Surgery Annual Meeting
PDF Version Compendium of clinical presentations includes studies with up to 3.5 years of patient follow-up and over 400 eyes treated in 31 centers in both combination cataract and standalone use MENLO PARK, Calif., Sept. 16, 2022 (GLOBE NEWSWIRE) — Sight Sciences, Inc. announced today that its OMNI Surgical System will be featured in seven […]
Sight Sciences Announces Long-Term Safety and Effectiveness Data of Standalone Use of the OMNI® Surgical System in Patients with Open Angle Glaucoma
Three-year, standalone (not combined with cataract surgery) data shows the non-implantable minimally invasive glaucoma surgery effectively reduces intraocular pressure and reduces need for IOP-lowering medications in open-angle glaucoma patients
Sight Sciences Reports Second Quarter 2022 Financial Results
Sight Sciences Reports Second Quarter 2022 Financial Results August 11, 2022 PDF Version MENLO PARK, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today reported financial results for the second quarter ended […]
Sight Sciences to Report Second Quarter 2022 Financial Results on August 11, 2022
MENLO PARK, Calif., July 28, 2022 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced it will report financial results for the second quarter ended June 30, 2022, after the market close on Thursday, August 11, 2022. […]